31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients by Reyngoudt, Harmen et al.
  1   
1. Title: 
 
31P-MRS demonstrates a reduction in absolute concentrations of high-energy phosphates in 
the occipital lobe of migraine without aura patients 
 
 
2. Authors: 
 
Harmen Reyngoudt1,2 
1Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium 
2Ghent Institute for Functional and Metabolic Imaging, Ghent University, Ghent, Belgium 
 
Koen Paemeleire, MD, PhD3,4 
3Department of Basic Medical Sciences, Ghent University, Ghent, Belgium 
4Department of Neurology, Ghent University Hospital, Ghent, Belgium 
 
Benedicte Descamps1,2 
1Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium  
2Ghent Institute for Functional and Metabolic Imaging, Ghent University, Ghent, Belgium 
 
Yves De Deene, PhD5,6 
5Laboratory for Quantitative Nuclear Magnetic Resonance in Medicine and Biology, Department of Radiation 
Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium 
6Department of Nuclear Medicine and Radiobiology, University of Sherbrooke, Sherbrooke, Quebec, Canada 
 
Eric Achten, MD, PhD1,2 
1Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium  
2Ghent Institute for Functional and Metabolic Imaging, Ghent University, Ghent, Belgium 
 
 
3. Correspondence to: 
 
Harmen Reyngoudt 
Ghent University Hospital 
MR-department, -1K12B 
De Pintelaan 185 
9000 Ghent, Belgium  
 
tel. +32 9 332 6425  
fax +32 9 332 49 69 
E-mail: harmen.reyngoudt@ugent.be 
 
 
4. Running title: 
 
31P-MRS demonstrates reduced energy metabolism in migraine without aura
  2   
ABSTRACT:  
Background: Differences in brain energy metabolism have been found between migraine 
patients and controls in previous phosphorus magnetic resonance spectroscopy (31P-MRS) 
studies, most of them emphasizing migraine with aura (MwA). The aim of this study was to 
verify potential changes in resting state brain energy metabolism in patients with migraine 
without aura (MwoA) compared to control subjects by 31P-MRS at 3 Tesla.  
Methods: Absolute metabolic quantification was performed using the phantom replacement 
technique. MRS measurements were performed interictally and in the medial occipital lobe of 
19 MwoA patients and 26 age-matched controls.  
Results: A significantly decreased phosphocreatine concentration ([PCr]) was found as in 
previous studies. While adenosine triphosphate concentration ([ATP]) was considered to be 
constant in previously published work, this study found a significant decrease in the measured 
[ATP] in MwoA patients. The inorganic phosphate ([Pi]) and magnesium ([Mg2+]) 
concentrations were not significantly different between MwoA patients and controls.  
Conclusions: The altered metabolic concentrations indicate that the energy metabolism in 
MwoA patients is impaired, certainly in a subgroup of patients. The actual decrease in [ATP] 
adds further strength to the theory of the presence of a mitochondrial component in the 
pathophysiology of migraine. 
 
KEYWORDS: 31P-MRS, creatine kinase reaction, migraine without aura, mitochondria, 
phantom replacement technique 
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INTRODUCTION 
 
Migraine is a common, disabling, primary headache disorder, with episodic manifestations 
that affects women three times more than men (1). Migraine is subdivided in two major 
subtypes: migraine without aura (MwoA) and migraine with aura (MwA), previously known 
as common and classic migraine, respectively (2). The aura is characterized by a gradual 
development of transient and reversible focal neurological symptoms, most often visual, and 
may be related to cortical spreading depression (3). The headache attack suggests a significant 
role of the activation of the trigeminovascular system (4). Migraine attacks are often triggered 
by external factors with psychological stress, hormones and fasting being the most common 
(5). 
Despite the high prevalence of migraine in the general population, the pathophysiology is still 
largely unknown. The current assumption is that subcortical structures, probably including 
brainstem, hypothalamus and thalamus, are involved in the generation of migraine attacks (6). 
Even more puzzling are the mechanisms at the basis of the interictal brain disorder that 
predisposes migraine patients to develop an attack. Until now no integrative model has been 
formulated that accounts for all the factors that may play a role in migraine neurobiology. 
Some of these factors include genetic background, nitric oxide hypersensitivity (7), cortical 
dyshabituation (8,9) and a disturbed energy metabolism. Genetic background and disturbed 
energy metabolism are discussed below. 
Twin studies and familial aggregation studies strongly suggest that migraine is genetically 
determined (10). The mode of inheritance is most likely multifactorial in both MwA and 
MwoA (11). No genetic mutations have been found in the common forms of migraine but a 
variety of gene polymorphisms, most often irreproducible, have been described (12). Recently 
though, the first genetic risk factor for migraine (MwA and MwoA) has been described (13). 
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Molecular genetic studies have not detected specific mitochondrial DNA (mtDNA) mutations 
in patients with migraine, although other studies suggest that particular genetic markers (i.e. 
neutral polymorphisms or secondary mtDNA mutations) might be present in some 
migraineurs (10,14). For instance, in migraineurs with occipital stroke (15) as well as in 
children with MwoA or cyclic vomiting, which can be a migraine equivalent (16), an 
increased number of mutations were detected in the noncoding control regions of mtDNA. 
The noncoding region of mtDNA has an extremely high mutation rate and is therefore highly 
polymorphic. Collections of mtDNA mutations derived from the same ancestor (i.e. 
haplogroups) can influence oxidative phosphorylation performance and could thus play a 
more subtle role in migraine pathogenesis, predisposing subjects to the disorder (14). A 
monogenic subtype of migraine is familial hemiplegic migraine, a rare form of MwA, in 
which three known different missense mutations have been found, all causing ionopathies, 
affecting ion homeostasis and eventually leading to cortical hyperexcitability by increasing 
synaptic glutamate levels, involved in the generation of an aura (17). No convincing evidence, 
however, has been obtained that these same genes play a major role in the common forms of 
migraine (12). 
In vivo energy metabolism can be studied by phosphorus magnetic resonance spectroscopy 
(31P-MRS). This technique allows for the non-invasive quantification of phosphorylated 
compounds including high-energy phosphates such as adenosine triphosphate (ATP) and 
phosphocreatine (PCr) and low-energy phosphates such as inorganic phosphate (Pi). 31P-MRS 
can also determine intracellular pH (pHi) and intracellular magnesium (Mg2+). In addition, 
adenosine diphosphate (ADP) and the phosphorylation potential (PP) can be calculated based 
on the creatine kinase equilibrium. Fig. 1 shows resting state brain energy metabolism and the 
corresponding metabolites that can be detected by 31P-MRS. In the past twenty years several 
31P-MRS studies suggested an abnormal cerebral energy metabolism in migraine patients 
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during ictal and interictal periods (see Table 1 for a review). These alterations concern energy 
metabolism and are not limited to the brain but have also been observed in muscle 
(22,23,24,27,30). The reduced energy potential was interpreted as being indicative of a 
reduced mitochondrial reserve and was hypothesized to be the biochemical substrate of the 
susceptibility to migraine attacks (28,31). As summarized in Table 1, studies have been 
performed in a wide variety of migraine subtypes, during either the ictal or interictal period, 
mostly localized in the occipital lobe and mostly in patients who did not undergo prophylactic 
treatment. In several of these studies, the migraine patient group was heterogeneous and 
information about the attack frequency was scarce. These studies were performed at different 
field strengths and provided little information, if any, about the quantification procedure of 
the metabolites. Most importantly, the ATP concentration ([ATP]) was always assumed 
constant and equal to normal controls, being 3 mM (32) or was not mentioned at all. 
However, cortical ATP levels can be decreased, as was demonstrated with 31P-MRS in other 
pathologies, such as systemic lupus erythematosus (33), episodic ataxia type 2 (34), 
progressive supranuclear palsy (35) and Parkinson’s disease (36). 
In this study the aim was to revisit quantitative 31P-MRS at 3 Tesla in the medial occipital 
lobe in patients with migraine without aura in the interictal phase, using absolute 
quantification based on the phantom replacement technique.  
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MATERIALS AND METHODS 
 
Patients and control subjects 
 
Nineteen MwoA patients fulfilling all required inclusion criteria (vide infra) were recruited by 
the local headache clinic. The control group consisted of twenty-six volunteers which were 
matched in age but not in gender. The details of the MwoA patients and the controls are given 
in Table 2. 
The study was approved by the local ethics committee and all subjects gave written informed 
consent. The migraine patients were diagnosed with MwoA according to the criteria of the 
International Headache Society (2). Patients experienced 2-8 attacks per month, were not 
using any prophylactic medication and were attack-free for at least 48 hours. None of the 
nineteen patients experienced a migraine attack within 24 hours after the spectroscopy study.  
 
31P-MRS and region of interest 
 
All measurements were performed on a 3 Tesla Siemens TrioTim whole-body scanner 
(Erlangen, Germany), using a 26.5-cm-diameter quadrature dual tuned (31P-1H) 
transmit/receive birdcage head coil (Rapid Biomedical, Würzburg-Rimpar, Germany). Spectra 
were acquired using a two-dimensional chemical shift imaging (CSI) phase-encoding scheme 
applying a pulse-free induction decay sequence. Manual shimming of the B0 magnetic field 
and manual optimization of the transmitter pulse power were used. 
The field of view (FOV) was placed occipital, covering the visual cortex (Fig. 2a en 2b), 
localized on T1-weighted gradient-echo images in three orthogonal planes with a slice 
thickness of 1 mm, a repetition time (TR) of 1550 ms and an echo time (TE) of 2.37 ms.  
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A 240 x 240 x 30 mm3 two-dimensional CSI-slice was recorded. Phase-encoding was used 
with a weighted acquisition scheme, resulting in an axial slice with a nominal thickness of 30 
mm and 30 x 30 mm2 in plane resolution (4 averages, flip angle of 90°, TR of 4000 ms and 
TE of 2.3 ms).  The raw data of each acquisition consisted of 1024 complex-valued data 
points, at a sampling period of 0.4 ms. The corresponding bandwidth was 2500 Hz. The total 
duration of the measurement was approximately 10 minutes.  
 
External calibration 
 
Signal intensities were quantified in terms of absolute concentrations by the phantom 
replacement technique. The reference phantom contained an aqueous solution (pH 7) of 10 
mM PCr (Sigma Aldrich). Sodium chloride (NaCl) and sodium azide (NaN3) were added to 
change the conductivity and to avoid mycotic growth, respectively. The phantom was made of 
plastic, was spherical and had a diameter of 10.4 cm. 
The complete equation for calculating the absolute in vivo concentrations is given by: 
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with subscripts i and r corresponding with the in vivo measurement and the reference phantom 
measurement, respectively.  [C] is the metabolite concentration, S is the signal strength, V is 
the volume of the voxel from which the signal is acquired, N is the number of phosphorus 
atoms that contribute to the spectral line (N = 1 in all cases), T is the absolute temperature (Ti 
= 37 °C in the human subject and Tr = 21 °C in the reference phantom), cload is a correction 
factor for different coil loading (i.e. the respective transmitter voltages, Vtra). The volume ratio 
Vr/Vi cancels from the equation since V was the same in the reference phantom and in vivo, 
i.e. 30 ml. All concentrations are expressed in mM. 
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Spectral analysis 
 
Fig. 2c shows a typical 31P-spectrum. The 31P resonances can be allocated to ATP, PCr, 
phosphodiesters (PDE), phosphomonoesters (PME) and Pi. The 31P-MRS spectra for ATP 
contain three signals corresponding to the three phosphorus nuclei of the molecule: the α-ATP 
resonance contains contributions from both NADH and α-ADP, the γ-ATP resonance contains 
contributions from β-ADP, and β-ATP is proportional to the total cellular ATP content. We 
therefore used the β-ATP resonance to quantify [ATP] (37). Following apodization 
(exponential filter, width = 110 ms) and zero-filling, the Fourier transformed free induction 
decays were phase and baseline corrected. Peak areas were obtained by the classical 
Levenberg-Marquardt frequency domain fitting method, using the software on the scanner 
(syngoMR B15, Numaris 4) (Fig. 2d). 
 
Creatine kinase reaction 
 
pHi was calculated from the chemical shift of Pi in relation to PCr (38). Brain cytosolic free 
[Mg2+] was assessed by a semi-empirical equation that correlates the chemical shift of the β-
ATP signal from PCr to the free [Mg2+] (39). 
The biochemical equation for the creatine kinase reaction is as follows: 
 
 PCr + ADP + H+ ⇌ ATP + Cr   (2) 
 
where Cr is creatine.  
The cytosolic ADP concentration ([ADP]) was calculated based on this equilibrium: 
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where the in vitro value of 1.66 109 M-1 is used for the creatine kinase equilibrium constant 
Kck (40). [Cr] is calculated from the measured PCr concentration ([PCr]), and [H+] is the 
proton concentration derived from the measured pH.  The tCr concentration, measured with 
proton magnetic resonance spectroscopy (1H-MRS), contains both contributions from both Cr 
and PCr.  For tCr, no significant changes have been found between MwoA patients and 
controls in a recent 1H-MRS study by our group (41). [ATP] is calculated from the β-ATP 
resonance (37). In addition, the phosphorylation potential (PP), an index of free available 
energy per ATP, was calculated as follows: 
 
[ ]
[ ][ ]iPADP
ATPPP =    (4) 
 
Statistical analysis 
 
Statistical analysis was performed using the SPSS software (SPSS 15.0 for Windows; 
Chicago, IL). Descriptive statistics was applied for age, Vtra, absolute metabolite 
concentrations and calculated values. A Wilcoxon Rank-Sum test was applied to compare 
Vtra, absolute metabolite concentrations and calculated values between MwoA patients and 
controls. Results were considered to be significant at P < 0.05. 
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RESULTS 
 
Table 3 shows the absolute concentrations of PCr, Pi and ATP as well as calculated values for 
pHi, ADP, PP and Mg2+ with their corresponding standard deviations, in the medial occipital 
lobe of 19 MwoA patients and 26 healthy volunteers. These values were obtained after 
applying corrections for coil loading and temperature.  
First of all, no significant differences were observed for all variables between males and 
females in the control group (data not shown). 
A significantly low PCr content was found in MwoA patients (P = 0.001). We also fitted the 
β-ATP signal to calculate the absolute [ATP]. On average, the ATP content was found to be 
significantly lower in MwoA patients compared to controls (P = 0.023). This corresponds 
with an average reduction of [ATP] by approximately 15 %. A subgroup of the MwoA 
patients (i.e., 20 %) demonstrates [ATP] values at least 2 standard deviations beneath the 
average [ATP] of controls, as illustrated in Figure 3. This subgroup corresponds with those 
patients who had the highest attack frequency.  
Mean [Pi] showed no significant difference between the MwoA patient group and the controls 
(P = 0.129). Calculated values of pHi and [ADP] showed no differences between MwoA 
patients and controls (P = 0.702 and P = 0.735, respectively). The PP was significantly 
decreased in the MwoA patient group (P = 0.041). Finally, the Mg2+ content did not 
demonstrate a significant difference between MwoA patients and controls (P = 0.254). 
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DISCUSSION 
 
31P-MRS provides a reliable non-invasive tool for the in vivo assessment of mitochondrial 
functionality by measuring cytosolic [ATP], [PCr], and [Pi] and by calculating [ADP], PP, pH 
and [Mg2+], all playing crucial roles in the creatine kinase equilibrium (Fig. 1).  
In migraine, several magnetic resonance spectroscopy studies, in particular 31P-MRS, have 
been performed. These studies were the first to document intrinsic biochemical abnormalities 
in migraine. In most of these studies, data was obtained in patients with migraine with 
prolonged aura (MwpA) and MwA patients, including patients with familial hemiplegic 
migraine (Table 1). Only two studies emphasized MwoA, in which measurements were 
performed interictally (24,28). 
To assess the resting state brain energy metabolism, we performed 31P-MRS on a 3 T high-
field in the medial occipital lobe of MwoA patients, who were attack-free and were not using 
any prophylactic medication, and compared the results with previous 31P-MRS studies. It is 
worth underlining the aim was to study a very homogeneous group of migraine patients who  
experienced a well-defined number of attacks (2 to 8 per month). This is in contrast to several 
other studies in which a heterogeneous group of migraine patients were examined and in 
which information about the attack frequency is not always available (21,25). By focusing on 
migraine without aura, the potential influence of the predisposition to aura, which is most 
often visual and thus related to the occipital cortex too, was avoided in this study. The chance 
of migraine attack-related brain disturbances was minimalized by examining the patients 
interictally, by assuring patients were at least 48 hours pain free before the procedure and at 
least 24 hours pain free after the procedure. 
We calibrated the in vivo spectra to an external standard to quantify absolute metabolite 
concentrations rather than using raw signal intensities.  
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As we were looking for metabolic disturbances, measurements were performed in the 
occipital lobe since it is found that the regional cerebral metabolic oxygen rate (CMRO2) is 
significantly higher in this brain area compared to other cortical regions (42). Additionally, 
the regional cerebral metabolic glucose rate (CMRgl) was found the highest in occipital white 
matter and the visual cortex (43). An additional advantage is that the visual cortex remains 
metabolically unchanged with advancing age (44). 
High-energy phosphate metabolism was found to be altered in MwoA patients in the medial 
occipital lobe. The average PCr concentrations were decreased significantly which is 
comparable with previous data (24). However, others could not confirm this (28). In contrast 
to all other 31P-MRS studies in migraine, in this study [ATP] was calculated from the 
spectrum. All other 31P-MRS studies in migraine assumed a constant [ATP] of 3 mM 
(22,23,24,25,26,27,28). This assumption was based on a 31P-MRS study in healthy subjects 
(32). We observed a significant decrease in the average [ATP] of approximately 15 % in 
MwoA patients as compared to controls.  
The PP is an index of mitochondrial functionality and of the energy status of the cell. The 
higher the PP, the more free energy is available in the cell. The PP was significantly 
decreased in MwoA patients compared to controls. This is in concordance with the findings in 
previous studies (23,24). ADP is the major driving force for mitochondrial energy production. 
The concentration of free cytosolic ADP is in the micromolar range and is below the 
sensitivity of MR spectroscopy in vivo. However, [ADP] can be calculated from the creatine 
kinase equilibrium. In contrast to most other studies, we did not find a difference between 
MwoA patients and controls. In all other studies, [ADP] was derived assuming an ATP 
concentration of 3 mM in both MwoA patients and controls. When calculating [ADP] 
assuming a constant [ATP] in our subjects, there was still no significant difference in [ADP] 
between MwoA patients and controls.  
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No cytosolic pH difference was found between MwoA patients and controls, as was also the 
case in previous studies (24,28).  
Mg2+ is an important enzymatic cofactor and can influence the equilibrium constant of several 
biochemical reactions, including the creatine kinase reaction. Brain cytosolic free [Mg2+] was 
not significantly different in MwoA patients compared to controls. In a previous study, a 
significant decrease in interictal [Mg2+] was found in MwA patients (27). In another study, 
whereas a significantly reduced brain [Mg2+] was observed ictally in both MwA and MwoA 
patients, this was not the case for interictal brain [Mg2+] in some of the patients (45). The 
absence of a significant interictal reduction of [Mg2+] may be attributed to the large 
heterogeneity of the patient group, the variability of the examined brain area examined, or the 
semi-empirical method to calculate [Mg2+].  
The decrease in high-energy phosphates suggests a mitochondrial component in the 
neurobiology of migraine. The brain is one of the most energy expensive tissues and although 
it comprises only 2-3 % of the total body weight (46), it utilizes approximately 25 % of the 
total glucose. The baseline metabolic rate of the brain is very high and most energy is thought 
to support glutamatergic neurotransmission, at least in the cortical grey matter (47). The brain 
at rest relies almost entirely on aerobic metabolism with glucose as the principal fuel (48). 
Glycogen can also be used but is only found in small amounts in the astrocytes (49). Lactate, 
an indicator of anaerobic glycolysis, accumulating in case of mitochondrial dysfunction, can 
be detected by 1H-MRS (50). A recent resting state 1H-MRS study did not show any 
quantifiable lactate in the visual cortex of MwoA patients (41). The observed decrease in 
[ATP], often called the ‘molecular unit of currency’ of intracellular energy transfer, might 
thus be explained by a decrease in ATP production through aerobic glycolysis and oxidative 
phosphorylation (Fig. 1). We emphasize that the decrease of high-energy phosphates in 
MwoA was detected at rest (interictally), implying the constant nature of this energy 
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disturbance rather than being a transient phenomenon. This cannot be explained by 
hypermetabolism as a recent [18]fluorodeoxyglucose-PET study in migraine patients failed to 
show any hypermetabolic brain regions, including in the occipital lobe (51). 
Is the reduction of interictal [ATP] related to a decrease in the number of mitochondria or to a 
decrease in mitochondrial efficiency? It is very difficult to draw conclusions in this regard 
since the brain is not readily accessible for histological and biochemical studies. There is, 
however, additional evidence for a mitochondrial component in migraine pathophysiology.  
With 31P-MRS, a decreased post-exercise recovery of high-energy phosphates was found in 
the gastrocnemius muscle of MwoA patients compared to controls (24,52). Platelet 
mitochondrial enzyme activities were found significantly lower in MwoA patients than in 
controls (53). Plasma lactate and pyruvate levels were found significantly increased in 
migraine patients compared to controls (54). Alterations comparable to those in migraine have 
been found in mitochondrial encephalomyopathies, and could conceivably result either from 
errors in energetic, oxidative pathways limiting the energy supply of cells, or to defects in 
ionic conductances or some specific neurotransmitters, responsible for neuronal excitability, 
whose failure increases energy expenditure in excitable cells (55). Stroke-like episodes and 
migraine are the predominant symptoms of mitochondrial encephalomyopathy with lactic 
acidosis and stroke-like episodes (MELAS), but the mtDNA point mutations at bp 3243 and 
3271, generally associated with this syndrome, were not found in migraine (56). 31P-MRS 
studies in mitochondrial diseases such as MELAS show similar results as in migraine both in 
brain (57) and in muscle (58). In both aforementioned studies no data concerning [ATP] is 
shown or [ATP] is, surprisingly, assumed constant, respectively. An occasional mtDNA 
mutation has been found in one study (59), however, this was not the case in systematic 
studies (60). Additionally, another study showed mitochondrial abnormalities in muscle 
biopsies of some migraine patients compared to controls (30). Mitochondrial metabolic 
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enhancers such as riboflavin (61) and coenzyme Q10 (62) have a prophylactic effect in a 
subgroup of migraine patients. Response to riboflavin seems to be related to a specific 
mitochondrial haplotype (14). 
Stress, female hormones and fasting are the most common trigger factors for migraine attacks 
(5). Normobaric hypoxia is able to trigger a migraine attack (63), as well as hypoglycaemia 
(5) in a subgroup of patients. It is intuitive to think that such specific triggers, having a direct 
effect on oxygen and glucose metabolism, respectively, would put a significant strain on the 
mitochondria. The hormones progesterone and oestrogen regulate oxidative metabolism in 
brain mitochondria (64). It has also been shown, albeit in cardiac myocytes, that 
noradrenaline, a typical stress mediator, causes calcium overload and results in a decreased 
mitochondrial respiration (65). Stress activates the noradrenergic locus coeruleus (66), which 
projects widely to the cortex, including the occipital visual cortex (67).  
A mitochondrial defect may reduce the threshold for migraine. The hypothesis of migraine 
being a “biobehavioural” (68) or a threshold disorder (69) states that it is a disorder in which 
an intrinsic metabolic defect renders the brain more susceptible to various factors that trigger 
an attack. It is hypothesized that trigger factors would act by increasing the metabolic energy 
demand or decreasing the metabolic energy supply. When a certain metabolic threshold is 
reached in the brain which is already near to its maximum energetic capabilities, a metabolic 
crisis could be induced which is responsible for the headache attack. Our data show that 
[ATP] is profoundly reduced in a subgroup of MwoA patients. Rather than being a generic 
component of migraine neurobiology, we hypothesize that a reduced mitochondrial energy 
reserve may be one of the many factors determining the migraine threshold. This hypothesis 
is in line with the observation that a subgroup of migraine patients respond to mitochondrial 
enhancers, such as riboflavin (61) and coenzyme Q10 (62), and that this response may be 
related to a specific mitochondrial haplotype (14). 
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In conclusion, a significant depletion of high-energy phosphates, both ATP and PCr, was 
found at rest in the medial occipital lobe of MwoA patients, compared to controls. This 
suggests a decrease in oxidative phosphorylation and implies a mitochondrial component in 
the pathophysiology of migraine without aura. A decreased mitochondrial energy reserve is 
pivotal in lowering the threshold for a migraine attack, at least in a subgroup of patients. It has 
to be emphasized that also other factors such as cortical dyshabituation, nitric oxide 
hypersensitivity and genetic aspects play crucial roles in migraine pathophysiology. 31P-MRS 
is sensitive enough to reveal defects of cell energy production of MwoA patients even in the 
absence of any symptoms and signs.  
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Fig. 1. Resting state brain energy metabolism. Adapted from Kemp et al, 2000 (18). In the resting state, 
intracellular adenosine triphosphate (ATP) results from the balance between ATP use and ATP synthesis. ATP is 
derived almost exclusively from mitochondrial oxidative phosphorylation, depending on glucose and oxygen 
supply. Changes in phosphocreatine (PCr) reflect the time integral of the mismatch between ATP usage and 
supply, as adenosine diphosphate (ADP) can be rephosphorylated through the creatine kinase reaction, with 
conversion from PCr to creatine (Cr). Magnesium (Mg2+) is bound to ATP in order for ATP to be biologically 
active. The metabolites in boxes can be detected by 31P-MRS. 
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Fig. 2. 
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Fig. 2. (a) Axial T1-weighted image and (b) sagittal T1-weighted image with the field-of-view and the voxel in 
the medial occipital lobe. (c) A spectrum acquired in the chosen voxel. (d) The same spectrum with curve fitting. 
A CSI-slice of (240 x 240 x 30) mm3 was placed and the nominal voxel volume was 30 ml. 
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Fig. 3. 
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Fig. 3. Distribution of the concentrations of the high-energy phosphates ATP and PCr. Mean concentrations are 
illustrated with a horizontal line. The mean minus 2 times the standard deviation is also shown. Note that in 
every plot 4 patients have concentrations beneath this threshold. These patients are not the same for the two 
plots. In the case of [ATP], these values correspond with the patients who had the highest attack frequency. 
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Tables 
 
Table 1. Literature survey of 31P-MRS studies performed in the brain of migraine patients. 
Study Migraine type (n)a ictal/ 
interictal 
study 
Brain region Prophylaxis 
at time of 
study? 
Field strength 
(T) 
[ATP] (mM) Results 
Welch et al, 1988 (19), 
Welch  et al, 1989 (20) 
MwoA (12), MwA 
(8) 
ictal occipital yes 1.89 - PCr/Pi ↓ 
Barbiroli et al, 1990 
(21) 
MwpAb (4), MSc (4) interictal occipital no 1.5 - PCr/Pi ↓ 
Sacquegna et al, 1992 
(22) 
MwpA (1) interictal occipital -e 1.5 3 [Pi] ↑, PP ↓ 
Barbiroli et al, 1992 
(23) 
MwA (12) interictal occipital no 1.5 3 pH  ↓, [PCr]  ↓, [ADP] ↑, PP ↓, 
Montagna et al, 1994 
(24), Montagna et al, 
1995 (25) 
MwoA (22), MwA 
(18), otherd (15) 
interictal occipital no 1.5 3 [PCr]  ↓, [ADP] ↑, PP ↓ 
Uncini et al, 1995 (26) FHM (5) interictal occipital - 1.5 3 [PCr]  ↓, [Pi] ↑, PP↓, [ADP] ↑ 
Lodi et al, 1997 (27) MwA (12), MwpA 
(3) 
interictal occipital no 1.5 3 [PCr]  ↓, [Pi] ↑, [ADP] ↑, PP ↓, [Mg2+] ↓, 
pH ↑ 
Boska et al, 2002 (28) MwoA (19), MwA 
(19), FHM (8) 
interictal occipital no 3 3 [Mg2+]  ↓, [PDE] ↑ 
Schulz et al, 2007 (29) MwA (22) interictal basal ganglia - 2 - PCr/Pi  ↓, Pi/ATP ↑ 
an = number of patients,  bMwpA = migraine with prolonged aura, cMS = migrainous stroke, dother = MS or MwpA, e‘-‘ = information not mentioned in the study 
[PCr] = phosphocreatine, [Pi] = inorganic phosphate, PP = phosphorylation potential, [ADP] = adenosine diphosphate, [ATP] = adenosine triphosphate, [Mg2+] = magnesium, 
[PDE] = phosphodiesters, [ ] are molar concentrations, PCr/Pi and Pi/ATP are ratios
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Table 2. Characteristics of participants. 
 patients controls 
Number of volunteers (n) 19 26 
Age (years, mean ± SD) 32.3 ± 12.1  27.6 ± 10.9 
Males 1 11 
Females 18 15 
Attack frequency per month (mean ± SD) 3.6 ± 1.1 - 
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Table 3. Concentration values in arbitrary units and calculated values (mean ± SD). 
 
MwoA patients controls P 
pHi  7.03 ± 0.09 7.03 ± 0.03 0.702 
[PCr] (mM) 4.09 ± 0.58* 4.85 ± 0.60 0.001* 
[Pi] (mM) 1.32 ± 0.50 1.06 ± 0.36 0.129 
[ATP] (mM) 2.33 ± 0.63* 2.76 ± 0.59 0.023* 
[ADP] (mM) 0.020 ± 0.006 0.018 ± 0.009 0.735 
PP (mM-1) 88.71 ± 21.95* 144.35 ± 18.12 0.041* 
[Mg2+] (mM) 0.135 ± 0.058 0.156 ± 0.038 0.254 
* Level of significance P < 0.05  
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Abbreviations used:  
1H-MRS, proton magnetic resonance spectroscopy; 
31P-MRS, phosphorus magnetic resonance spectroscopy; 
ADP, adenosine diphosphate; 
ATP, adenosine triphosphate; 
cload, correction factor for coil loading; 
Cr, creatine; 
CSI, chemical shift imaging; 
FHM, familial hemiplegic migraine; 
FOV, field of view; 
MS, migrainous stroke; 
mtDNA, mitochondrial DNA; 
MwA, migraine with aura; 
MwoA, migraine without aura; 
MwpA, migraine with prolonged aura; 
N, number of protons; 
PCr, phosphocreatine; 
Pi, inorganic phosphate; 
PP, phosphorylation potential 
ρ, density; 
S, signal amplitude; 
T, temperature; 
TE, echo time; 
TR, repetition time; 
tCre, total creatine; 
V, voxel volume; 
VOI, volume of interest; 
Vtra, transmitter voltage 
